Cancer Treatment Reviews
Volume 29 , Pages 33-39 , May 2003

Clinical update: proteasome inhibitors in hematologic malignancies

  • Paul Richardson

      Affiliations

    • Corresponding Author InformationCorrespondence to: Paul Richardson MD, Jerome Lipper Multiple Myeloma Center, Division of Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. Tel.: 1-617-632-2104; Fax: 1-617-632-6624

References 

  1. Shah SA, Potter MW, McDade TP, et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 2001;82(1):110–122
  2. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 2001;100(1):11–17
  3. Cusack JC, Liu R, Houston M, et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition. Cancer Res. 2001;61(9):3535–3540
  4. Hideshima T, Richardson P, Chauhan D, et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–3076
  5. Ma MH, Parker KM, Manyak S, et al.  Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway. Blood. 2001;98(11):437a
  6. Russo SM, Tepper JE, Baldwin AS, et al.  Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 2001;50(1):183–193
  7. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-κB in the biology and treatment of multiple myeloma. Semin. Oncol. 2001;28(6):626–633
  8. LeBlanc R, Catley LP, Hideshima T, et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62(17):4996–5000
  9. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93(5):1658–1667
  10. Chauhan D, Uchiyama H, Akbarali Y, et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996;87(3):1104–1112
  11. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial–leukocyte adhesion molecule expression. Immunity. 1995;2(5):493–506
  12. Hideshima T, Mitsiades C, Akiyama M, et al.  Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood. 2003;101(4):1530–1534
  13. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2002; published online
  14. Pham L, Tamayo A, Lo P, Yoshimura L, Ford RJ. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood. 2001;98(11):465a
  15. Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma. 2002;3(1):49–55
  16. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001;194(12):1861–1874
  17. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001;61(15):5926–5932
  18. Adams J, Palombella VJ, Sausville EA, et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615–2622
  19. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002;20(21):4420–4427
  20. Aghajanian C, Soignet S, Dizon DS, et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002;8(8):2505–2511
  21. Blade J, Samson D, Reece D, et al.  Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 1998;102(5):1115–1123
  22. Richardson P, Barlogie B, Berenson J, et al.  A phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™ formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. Blood. 2002;100(11):104a
  23. Richardson PG, Barlogie B, Berenson J, et al. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/refractory disease: results from cohort 1 analysis. Proceedings of the American Society of Clinical Oncology-38th Annual Meeting 2002; 21: 11a
  24. Jagannath S, Barlogie B, Berenson J, et al.  A phase II multicenter randomized study of the proteasome inhibitor bortezomib (VELCADE™, formerly PS-341) in multiple myeloma (MM) patients (pts) relapsed after front-line therapy. Blood. 2002;100(11):812a
  25. Papandreou C, Daliani D, Millikan RE, et al. Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (Pts) with advanced malignancies. Proceedings of the American Society of Clinical Oncology-37th Annual Meeting 2001; 20: 86a

PII: S0305-7372(03)00080-X

doi: 10.1016/S0305-7372(03)00080-X

Cancer Treatment Reviews
Volume 29 , Pages 33-39 , May 2003

Article Tools

* Image Usage & Resolution